13.32 USD
▲+0.35+2.86%
2026-08-03
市值
$387.32M
市盈率
—
EPS
-2.47
股息率
—
52 周区间
6.45 – 17.15
成交量
209.59K
Beta
0.97
目标价
21.17
52W 低 6.4552W 高 17.15
价格走势
公司简介
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...